Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | NAAA | Q02083 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13855308 | 0.89 | NAAA (0.45) | RAB9ANPC1NAAAALDH1A1EPHX1 | |
| SCHEMBL112859 | 0.89 | ALDH1A1 (0.64) | RAB9ANPC1ALDH1A1LMNATSHR | |
| SCHEMBL12885341 | 0.88 | ALDH1A1 (0.44) | RAB9ANPC1NAAAALDH1A1EPHX1 | |
| Hydrochloric Acid SCHEMBL29090140 | 0.87 | ALDH1A1 (0.62) | RAB9ANPC1ALDH1A1LMNATSHR | |
| Ammonia Solution, Strong SCHEMBL27788705 | 0.87 | ALDH1A1 (0.62) | RAB9ANPC1ALDH1A1LMNATSHR | |
| SCHEMBL15762727 | 0.87 | ALDH1A1 (0.48) | ALDH1A1LMNA | |
| SCHEMBL28178911 | 0.86 | NAAA (0.50) | RAB9ANPC1NAAAALDH1A1EPHX1 | |
| SCHEMBL260370 | 0.86 | MMP12 (0.45) | RAB9ANPC1NAAAALDH1A1AGXT | |
| Acetic Acid SCHEMBL27664299 | 0.85 | ALDH1A1 (0.66) | RAB9ANPC1ALDH1A1LMNAMAPT | |
| SCHEMBL12733151 | 0.85 | NAAA (0.49) | RAB9ANPC1NAAAALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286233-A1 | PIPERIZINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, HPN, PREP | RAB9A 3267/4885NPC1 160/4885NAAA 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.